α ‐Hydroxybutyrate Association With Incident Type 2 Diabetes Over 10 Years Across Different Glycemic States
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.71155 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Elena Fortin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Medicine K2, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Blood Glucose, Glucose Intolerance, Hydroxybutyrates. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: DirectSens GmbH.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aim
To investigate the association between baseline plasma α‐hydroxybutyrate (α‐HB), an organic acid derived from aminoacid catabolism and glutathione anabolism, and the 10‐year incidence of Type 2 diabetes (T2DM). Materials and Methods This prospective study analysed 1349 participants from the Swedish PAROKRANK study. At baseline, participants without known diabetes underwent a standardised 2‐h oral glucose tolerance test and were categorised into four groups: normoglycemia, impaired fasting glucose, impaired glucose tolerance and T2DM. Incident T2DM was identified over a 9.95‐year median follow‐up via national registries. Plasma α‐HB concentrations were quantified using an enzymatic test kit (XpressGT). Risk of incident T2DM was analysed using uni‐ and multi‐variate Cox regression models. Model performance was further assessed using the category‐less Net Reclassification Improvement (NRI). Results α‐HB levels showed a stepwise elevation across the spectrum of dysglycemia at baseline. During follow‐up, 134 (11%) individuals developed T2DM. Each unit increase in log‐transformed α‐HB was associated with a nearly twofold increase in the risk of developing T2DM (HR 1.99; 95% CI 1.32–3.01) in the univariate analysis, which remained significant after adjustment for relevant clinical variables including BMI and fasting Hba1c (HR 1.78; 95% CI 1.19–2.67). The addition of α‐HB to a clinical model yielded a significant NRI improvement (0.23; p = 0.01).
Conclusions
Plasma α‐HB is a robust, independent risk marker of incident T2DM over a decade, which identifies long‐term metabolic risk not fully captured by glycaemic status alone. Its reliance on a single fasting measurement may offer a practical tool for refining early risk stratification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Department of Medicine K2, Karolinska Institutet, Stockholm, Sweden.
- Center for Diabetes, Academic Specialist Center, Region Stockholm, Stockholm, Sweden.
- Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
- Capio St Görans Hospital, Stockholm, Sweden.
- DirectSens GmbH, Vienna, Austria.
- Internal Medicine Unit, Södertälje Hospital, Södertälje, Sweden.
ORCID-Profile: Anna Norhammar, Giulia Ferrannini
Förderung
- DirectSens GmbH
Zitieren
APA
Fortin, E., Norhammar, A., Stadler, D., Herzog, P. L., Ferrannini, G., & Ferrannini, E. (2026). α ‐Hydroxybutyrate Association With Incident Type 2 Diabetes Over 10 Years Across Different Glycemic States. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71155
Vancouver
Fortin E, Norhammar A, Stadler D, Herzog PL, Ferrannini G, Ferrannini E. α ‐Hydroxybutyrate Association With Incident Type 2 Diabetes Over 10 Years Across Different Glycemic States. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71155
BibTeX
@article{Fortin2026,
author = {Fortin, Elena and Norhammar, Anna and Stadler, David and Herzog, Peter L and Ferrannini, Giulia and Ferrannini, Ele},
title = {α ‐Hydroxybutyrate Association With Incident Type 2 Diabetes Over 10 Years Across Different Glycemic States},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.71155}
}
EUVIMED